- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Hims Hers Health Inc(HIMS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HIMS
11/13/2026: HIMS (1-star) is currently NOT-A-BUY. Pass it for now.
Hims & Hers Health Inc is a high-growth telehealth platform that provides consumers with direct access to medical treatments for various lifestyle conditions. Its business strength lies in a strong brand, a scalable subscription model, and the ability to offer personalized treatments through internal compounding. The company's primary growth opportunity centers on expanding its footprint in high-demand areas like weight loss and mental health. However, investors face risks, including potential regulatory changes in telehealth prescribing and intense competition from established health retailers. The stock may best suit growth investors comfortable with volatility, while stakeholders should closely monitor regulatory news and subscriber retention metrics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company exhibits rapid revenue expansion and aggressive market penetration in high-demand health categories. |
| Momentum investor | Strong fit while signal remains positive | Strong revenue growth and shifting sentiment around weight-loss offerings make this a potential target for momentum-based strategies. |
| Value investor | Weak fit | The company is valued primarily on future growth prospects rather than current cash flow or asset value. |
| Dividend investor | Weak fit | The company reinvests all available capital into growth and does not pay a dividend. |
| Low-risk investor | Weak fit | High volatility and regulatory uncertainties make this stock unsuitable for conservative, risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Growth-stage stocks often experience wide price swings based on sentiment and quarterly subscriber data. |
| Valuation risk | Medium / high | Future growth expectations are already reflected in the premium valuation. |
| Competition risk (Direct Telehealth) | High | The sector is crowded with well-capitalized incumbents and low-barrier-to-entry digital health startups. |
| Business quality | Medium | The company has a strong brand, but it remains dependent on marketing spend and variable regulatory environments. |
| Dividend income | Low / none | The business model is currently optimized for growth rather than capital returns. |
| Execution risk | Medium / high | Success depends on continuously acquiring subscribers while maintaining low churn and managing clinical complexity. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.62B USD | Price to earnings Ratio - | 1Y Target Price 28.31 |
Price to earnings Ratio - | 1Y Target Price 28.31 | ||
Volume (30-day avg) 13.8M shares | Beta 2.5 | 52 Weeks Range 13.74 - 40.99 | Updated Date 11/14/2026 |
52 Weeks Range 13.74 - 40.99 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 79.98% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Subscription Services | Recurring revenue from prescribed medications and wellness product shipments. | Most of the company's money comes from loyal customers who subscribe to ongoing health plans. |
| Consultation Fees | Fees charged for virtual visits with independent medical providers. | Small portion of revenue generated by the platform acting as a bridge between patients and doctors. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-09 | When After Market | Estimate 0.07 | Actual 0.03 |
Profitability
Profit Margin -6.65% | Operating Margin (TTM) -6.39% |
Management Effectiveness
Return on Assets (TTM) -3.96% | Return on Equity (TTM) -40.77% |
Valuation
Trailing PE - | Forward PE 51.28 | Enterprise Value 5.47B | Price to Sales(TTM) 1.61 |
Enterprise Value 5.47B | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 1.91 | Enterprise Value to EBITDA 205.86 | Shares Outstanding 226.03M | Shares Floating 214.85M |
Shares Outstanding 226.03M | Shares Floating 214.85M | ||
Percent Insiders 6.95 | Percent Institutions 68.12 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

